A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
August 31, 2024
Primary Completion Date
July 31, 2026
Study Completion Date
December 31, 2026
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DRUG
Cabozantinib
Cabozantinib (Cabometyx) 60, 40 and 20 mg
All Listed Sponsors
collaborator
Mahidol University
OTHER
lead
Chulalongkorn University
OTHER
NCT06535737 - A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab | Biotech Hunter | Biotech Hunter